Immunovant (IMVT) Share-based Compensation (2019 - 2026)

Immunovant (IMVT) has 8 years of Share-based Compensation data on file, last reported at -$44.5 million in Q1 2026.

• Quarterly Share-based Compensation fell 45518.37% year-over-year to -$44.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73000.0 (down 25.51% YoY) and the FY2026 annual result came in at $73000.0, down 25.51% from the prior year.
• Share-based Compensation slipped to -$44.5 million in Q1 2026, from $12.7 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $18.5 million in Q2 2025 to a low of -$44.5 million in Q1 2026.
• A 5-year average of $606117.6 and a median of $8.9 million in 2022 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2025 — Share-based Compensation surged 148.63% — and 2026, when it tumbled 45518.37%.
• Tracing IMVT's Share-based Compensation over 5 years: stood at $8.9 million in 2022, then rose by 14.75% to $10.2 million in 2023, then slumped by 355.85% to -$26.1 million in 2024, then surged by 148.63% to $12.7 million in 2025, then tumbled by 450.06% to -$44.5 million in 2026.
• The last three Share-based Compensation figures came in at -$44.5 million (Q1 2026), $12.7 million (Q4 2025), and $13.4 million (Q3 2025), per Business Quant data.